Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial

Trial Profile

The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Apr 2016 Status changed from recruiting to completed.
    • 28 Jun 2015 Planned number of patients changed from 39 to 25 as reported by ClinicalTrials.gov record.
    • 28 Jun 2015 Planned primary completion date changed to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top